Scarica l'app Stockscreener
3.91
11.71%
0.41
Dopo l'orario di chiusura:
3.85
-0.06
-1.53%
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World
Retinitis Pigmentosa Treatment Market Report: Detailed - openPR
Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail
Persistent Epithelial Defect Market Statistics Expected - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use - Marketscreener.com
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - Newsfile
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Yahoo Finance
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals CEO acquires $14.9k in company stock - Investing.com
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31% - Yahoo Finance
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem - Simply Wall St
Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2025 - MarketBeat
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - Yahoo Finance
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases - BioSpace
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):